RxDoctor Payments Data

Olga Khodakivska

Neurology · Palm Springs, CANPI 1902289440

Payments from drug & device makers

$5,980in general payments, 2019–2025

Across 69 payments — averaging $86.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$3K
  • AbbVie$594
  • Abbott$434
  • SK Life Science, Inc.$307
  • Neuropace, Inc.$265
  • Grifols USA, LLC$254
  • plus $998 from 8 others

What the payments were for

  • Travel & lodging$1,82931%
  • Food & beverage$4,13669%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,980 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$141,323
Medicare patients
538
Services billed
1,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant67$67,520
XcopriCenobamate15$38,341
Nurtec OdtRimegepant Sulfate30$31,254
ValtocoDiazepam12$29,177
BriviactBrivaracetam11$26,537
Aimovig AutoinjectorErenumab-Aooe18$17,911
QuliptaAtogepant14$15,029
NayzilamMidazolam13$10,874
Sumatriptan Succinate141$10,552
Levetiracetam191$6,893
Lacosamide55$6,404
Oxcarbazepine58$4,270
Gabapentin223$4,093
Topiramate128$1,972
Divalproex Sodium ErDivalproex Sodium25$1,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$594$82,55081 claims
SK Life Science, Inc.Xcopri$307$38,34115 claims
UCB, Inc.Briviact, Nayzilam$125$37,41124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in Palm Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →